Featured Chrome Extensions:

Casey IRACs are produced by an AI that analyzes the opinion’s content to construct its analysis. While we strive for accuracy, the output may not be flawless. For a complete and precise understanding, please refer to the linked opinions above.

Keywords

summary judgmentpatent
summary judgmentpatent

Related Cases

Jones v. United States, 168 A.3d 703
View Case »
Aqua Marine Supply v. AIM Machining, Inc., 247 F.3d 1216, 58 U.S.P.Q.2d 1536
View Case »
Coeur Alaska, Inc. v. Southeast Alaska Conservation Council, 557 U.S. 261, 129 S.Ct. 2458, 174 L.Ed.2d 193, 68 ERC 1513, 77 USLW 4559, 09 Cal. Daily Op. Serv. 7704, 2009 Daily Journal D.A.R. 8998, 21 Fla. L. Weekly Fed. S 973
View Case »
Classen Immunotherapies, Inc. v. Biogen IDEC, 659 F.3d 1057, 100 U.S.P.Q.2d 1492
View Case »
F.C.C. v. Sanders Bros. Radio Station, 309 U.S. 470, 309 U.S. 642, 60 S.Ct. 693, 84 L.Ed. 869, 84 L.Ed. 1037
View Case »
Justia Law Link
LexisNexis Link
Westlaw Link
CourtListener Link
Oyez Link

Hormone Research Foundation, Inc. v. Genentech, Inc., 904 F.2d 1558, 15 U.S.P.Q.2d 1039

Facts

In April 1971, Dr. Chao Hao Li filed a patent application for a synthetic human growth hormone (HGH) that later matured into the '833 patent. The application underwent revisions, leading to a different amino acid sequence than initially proposed. Hormone Research Foundation (HRF), the patent holder, alleged that Genentech's products, Protropin and Protropin II, infringed on its patent. The district court granted summary judgment in favor of Genentech, ruling that there was no literal infringement and that the patent claims were invalid for lack of enablement.

Issue

Did Genentech infringe the '833 patent, and were the claims of the patent enabling?

Did Genentech infringe the '833 patent, and were the claims of the patent enabling?

Rule

To determine patent infringement, the court must assess whether the claims have been properly interpreted and whether each limitation of the claims is found in the accused product. The interpretation of patent claims is a legal question, while the factual determination of infringement is based on the specific characteristics of the accused product. Additionally, prosecution history estoppel limits the doctrine of equivalents, preventing a patentee from recapturing coverage surrendered during prosecution.

To determine patent infringement, the court must assess whether the claims have been properly interpreted and whether each limitation of the claims is found in the accused product. The interpretation of patent claims is a legal question, while the factual determination of infringement is based on the specific characteristics of the accused product. Additionally, prosecution history estoppel limits the doctrine of equivalents, preventing a patentee from recapturing coverage surrendered during prosecution.

Analysis

The court found that Genentech's products did not literally infringe the '833 patent because they did not correspond to the structure depicted in Figure 2 of the patent. The interpretation of the term 'corresponding' was deemed to require identity in structure, which Genentech's products lacked. Furthermore, the court ruled that prosecution history estoppel applied, preventing HRF from claiming infringement under the doctrine of equivalents. The enablement issue was also addressed, with the court concluding that the patent claims were not enabling due to insufficient disclosure of how to produce the claimed polypeptide sequences.

The court found that Genentech's products did not literally infringe the '833 patent because they did not correspond to the structure depicted in Figure 2 of the patent. The interpretation of the term 'corresponding' was deemed to require identity in structure, which Genentech's products lacked. Furthermore, the court ruled that prosecution history estoppel applied, preventing HRF from claiming infringement under the doctrine of equivalents. The enablement issue was also addressed, with the court concluding that the patent claims were not enabling due to insufficient disclosure of how to produce the claimed polypeptide sequences.

Conclusion

The court affirmed the district court's ruling that Genentech did not infringe the '833 patent and that the patent claims were invalid for lack of enablement.

The court affirmed the district court's ruling that Genentech did not infringe the '833 patent and that the patent claims were invalid for lack of enablement.

Who won?

Genentech prevailed in this case as the court upheld the district court's summary judgment ruling that there was no literal infringement of the '833 patent and that the claims were invalid for lack of enablement. The court found that the interpretation of the patent claims was legally sound and that the prosecution history estoppel barred HRF from recovering under the doctrine of equivalents.

Genentech prevailed in this case as the court upheld the district court's summary judgment ruling that there was no literal infringement of the '833 patent and that the claims were invalid for lack of enablement. The court found that the interpretation of the patent claims was legally sound and that the prosecution history estoppel barred HRF from recovering under the doctrine of equivalents.

You must be